港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

抗疫概念

888.076

+9.2871.06%

漲家數：11

跌家數：6

平家數：- -

市盈率：- -

高：891.617

開：876.263

低：869.207

收：878.789

成交量：2.69億

成交額：21.23億

市值：6,002.36億

流通市值：4,968.65億

資料載入中...

總覽新聞資訊

同源康醫藥-B(02410.HK)獲董事長、執行董事兼總裁吳豫生增持35萬股

特朗普打出中期選舉組合拳：強推減税與「MAHA運動」，醫藥與加工食品板塊首當其衝

勁方醫藥-B(02595)9月9日斥資196.08萬港元回購7.5萬股

復星醫藥白癜風口服新藥獲批III期臨床

石藥集團：多巴胺受體激動劑羅替高汀長效注射液獲批臨床

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准

石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准

石藥集團戈舍瑞林緩釋注射劑（SYH9102）獲中國臨床試驗批准

復星醫藥(02196)9月9日斥資262.98萬港元回購15.25萬股

京東(09618.HK)發布新版京東App 推AI購物助手「東東」

阿斯达克财经

迪哲醫藥(688192.SH)：比瑞替尼治療瀰漫性大B細胞淋巴瘤研究成果獲《血液腫瘤期刊》發表

《大行》里昂：中國創新藥板塊重返Alpha主導宏觀波動或提供買入機會

阿斯达克财经

中銀國際：醫藥中報業績逐步修復行業進入反轉周期

阿里健康(00241)出現大手賣出110萬股，成交價$3.055，涉資336.05萬

阿斯达克财经

我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參

每日经济新闻

港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」

同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份

四川甘孜：農機助力川西高原秋收

中国新闻网

勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股

智通财经网

禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BK1515/news?page=4"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1515","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","market":"HK","secType":"PLATE","nameCN":"抗疫概念","latestPrice":888.07635,"timestamp":1789373282104,"preClose":878.7892,"halted":0,"volume":269268704,"delay":0,"changeRate":0.010568,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":9.28717,"latestTime":"09-14 16:00:00","open":876.263,"high":891.617,"low":869.2073,"amount":2123131721,"amplitude":0.025501,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"pbRate":1.318473,"peRate":17.086203,"turnoverRate":0.003534,"increases":11,"decrements":6,"flats":0,"marketCap":600236234944,"floatMarketCap":496865354048},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1515\",,,,,undefined,":{"symbol":"BK1515","high":891.617,"amplitude":0.025501,"preClose":878.7892,"low":869.2073,"pbRate":"1.318473","latestPrice":888.07635,"volume":269268704,"delay":0,"open":876.263,"prevYearClose":1190.107,"prevWeekClose":878.789,"prevMonthClose":925.265,"prevQuarterClose":802.777,"fiveDayClose":942.123,"twentyDayClose":915.795,"sixtyDayClose":842.862,"secType":"PLATE","market":"HK","turnoverRate":0.003534,"peRate":17.086203,"marketCap":600236234944,"floatMarketCap":496865354048,"timestamp":1789373282104,"nameCN":"抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1515\",,,,undefined,":{"bkCode":"BK1515","up":11,"down":6,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1515\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666392539","title":"同源康醫藥-B(02410.HK)獲董事長、執行董事兼總裁吳豫生增持35萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666392539","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666392539?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 22:17","pubTimestamp":1788963422,"startTime":"0","endTime":"0","summary":"格隆汇9月9日丨根据联交所最新权益披露资料显示，2026年9月8日，同源康医药-B(02410.HK)获董事长、执行董事兼总裁吴豫生在场内以每股均价3.4626港元增持35万股，涉资约121.2万港元。\n\n　　增持后，吴豫生最新持股数目为123,816,000股，持股比例由32.48%上升至32.57%。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202609/09/20260909128261.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202609/09/20260909128261.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260909/32365336.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","02410","BK1515","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536659","title":"特朗普打出中期選舉組合拳：強推減税與「MAHA運動」，醫藥與加工食品板塊首當其衝","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536659","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666536659?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 21:35","pubTimestamp":1788960918,"startTime":"0","endTime":"0","summary":"智通财经APP注意到，美国总统特朗普在11月中期选举前的助选热情不高、花钱也相当节省。白宫一年来一直承诺特朗普会外出为候选人助选，但实际成果寥寥。一位讨论特朗普周三晚达拉斯讲话的共和党官员表示，民主党已经在针对总统及其政策开展竞选，因此以全国性策略应对中期选举是合理的。鉴于选情，一些共和党人表示，特朗普主打基本盘是合理的。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494110.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159151","BK1574","BK1515","09939","159938","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538468","title":"勁方醫藥-B(02595)9月9日斥資196.08萬港元回購7.5萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538468?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 20:11","pubTimestamp":1788955898,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月9日，该公司斥资196.08万港元回购7.5万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494077.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","09939","02595","BK1574","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538734","title":"復星醫藥白癜風口服新藥獲批III期臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538734","media":"健识局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538734?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 19:42","pubTimestamp":1788954120,"startTime":"0","endTime":"0","summary":"近日，复星医药宣布，FXS5626片（原项目代号：AC-201）用于治疗非节段型白癜风开展II/III期适应性无缝设计临床试验已获药监局批准。从进度看，辉瑞利特昔替尼和诺诚健华soficitinib处于第一梯队，均已公布积极II/III期数据。复星医药FXS5626与华东医药VC005、恒瑞艾玛昔替尼大致处于第二梯队。 且国内白癜风口服在研管线中，FXS5626是目前唯一明确标注为TYK2/JAK1双靶点的品种。运营｜廿十三","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-09-09/doc-inirfums8444408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0175","600196","BK0183","BK1515","BK0060","BK1191","BK1593","BK0196","BK0188","BK0028","BK0187","BK0096","02196","BK0239","BK0012"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666778582","title":"石藥集團：多巴胺受體激動劑羅替高汀長效注射液獲批臨床","url":"https://stock-news.laohu8.com/highlight/detail?id=2666778582","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666778582?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:18","pubTimestamp":1788949080,"startTime":"0","endTime":"0","summary":"9月9日，石药集团（01093）发布公告，公司开发的多巴胺受体激动剂罗替高汀长效注射液（SYH9087注射液）已获国家药品监督管理局批准，可开展临床试验。公告提到，该产品为国内首个获批开展临床试验的皮下注射罗替高汀长效产品，利用本集团的长效递送技术平台，以具有良好生物相容性的辅料为基础，经皮下注射后形成原位药物贮库，从而可实现药物长效递送。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869445490.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869445490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999004220.SGD","LU1152091754.HKD","LU0140636845.USD","LU1226288170.HKD","LU1960683339.HKD","KURE","IE00BZ08YS42.EUR","LU2039709279.SGD","LU0067412154.USD","LU0072913022.USD","LU0326950275.SGD","01093","LU1813983027.USD","LU1226287875.USD","LU0501845795.SGD","IE0008368742.USD","IE00BZ08YR35.GBP","BK1515","BK1521","LU1226287792.SGD","LU1807302812.USD","IE00B5MMRT66.SGD","LU1008478684.HKD","IE0008369823.USD","BK1191","LU0880133367.SGD","IE00B031HY20.USD","LU1226287529.USD","LU1226288253.USD","HK0000165453.HKD","LU1152091168.USD","LU1951186391.HKD","LU0315179316.USD","LU1993786604.SGD","LU0314109678.HKD","IE00BZ08YT58.USD","LU1328277881.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666846135","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666846135","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666846135?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:09","pubTimestamp":1788948562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 发布公告，本集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液(该产品)已获中国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493973.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B5MMRT66.SGD","LU0314109678.HKD","01093","BK1515","IE00BZ08YR35.GBP","LU1226287792.SGD","IE00B031HY20.USD","LU1328277881.USD","PSYK","LU1813983027.USD","SG9999004220.SGD","IE00BZ08YS42.EUR","IE00B543WZ88.USD","IE0008368742.USD","LU1008478684.HKD","LU0326950275.SGD","LU1993786604.SGD","LU0880133367.SGD","LU1226287875.USD","BK1191","LU1152091754.HKD","LU0315179316.USD","LU1807302812.USD","LU1226288253.USD","LU2039709279.SGD","LU0140636845.USD","HK0000165453.HKD","LU1960683339.HKD","BMED","LU1226287529.USD","LU1226288170.HKD","IE00BZ08YT58.USD","BK1521","LU0072913022.USD","LU0067412154.USD","MDTX","IBBQ","KURE","LU1951186391.HKD","LU1152091168.USD","IBBJ","IE0008369823.USD","LU0501845795.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666584690","title":"石藥集團(01093)：戈舍瑞林緩釋注射液(SYH 9102注射液)在中國獲臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2666584690","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666584690?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948523,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团 公布，该集团开发的促性腺激素释放激素受体激动剂戈舍瑞林缓释注射液已获中华人民共和国国家药品监督管理局批准，可在中国开展临床试验。该产品为全球首款获批临床的即用型戈舍瑞林缓释注射液，可通过与垂体GnRH受体高亲和力结合并诱导受体降调节，抑制促性腺激素分泌，降低血清睾酮及雌二醇水平，实现药物去势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1813983027.USD","LU1152091168.USD","LU1951186391.HKD","LU2039709279.SGD","LU0314109678.HKD","IBBQ","IE00B5MMRT66.SGD","LU1993786604.SGD","IBBJ","LU1226288253.USD","HK0000165453.HKD","LU1960683339.HKD","LU0067412154.USD","IE00B031HY20.USD","LU1226287875.USD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","MDTX","LU0140636845.USD","BK1191","LU1328277881.USD","BK1521","LU1152091754.HKD","LU0315179316.USD","LU0501845795.SGD","BK1515","BMED","IE00BZ08YR35.GBP","LU1226287792.SGD","SG9999004220.SGD","LU1807302812.USD","PSYK","IE00B543WZ88.USD","IE0008368742.USD","LU0326950275.SGD","01093","LU1226287529.USD","LU1008478684.HKD","KURE","IE00BZ08YT58.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184219055","title":"石藥集團戈舍瑞林緩釋注射劑（SYH9102）獲中國臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1184219055","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184219055?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:08","pubTimestamp":1788948506,"startTime":"0","endTime":"0","summary":"石药集团宣布，其研发的戈舍瑞林缓释注射剂已正式获得中国国家药品监督管理局的临床试验批准。石药集团此次获批的缓释剂型，旨在提供更持久的药物释放效果，有望改善患者的治疗体验和依从性。获得临床试验批准后，石药集团将按照相关法规和伦理要求，组织开展一系列临床试验，以评估该注射剂的安全性、有效性和药代动力学特性。石药集团表示，将积极推进该产品的临床研发进程，并严格遵守国家药品监管的相关规定。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0315179316.USD","LU1226287529.USD","LU0326950275.SGD","LU0501845795.SGD","IE0008368742.USD","LU0880133367.SGD","IE00B031HY20.USD","LU0314109678.HKD","LU1328277881.USD","LU1813983027.USD","LU0067412154.USD","IE00BZ08YS42.EUR","LU0072913022.USD","LU1226288253.USD","LU1008478684.HKD","LU1951186391.HKD","IE00B543WZ88.USD","HK0000165453.HKD","BK1515","LU1226287792.SGD","IE00BZ08YR35.GBP","LU0140636845.USD","LU2039709279.SGD","LU1226287875.USD","SG9999004220.SGD","IE0008369823.USD","01093","LU1226288170.HKD","LU1807302812.USD","LU1152091168.USD","LU1960683339.HKD","BK1191","LU1993786604.SGD","KURE","IE00BZ08YT58.USD","BK1521","LU1152091754.HKD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666843785","title":"復星醫藥(02196)9月9日斥資262.98萬港元回購15.25萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666843785","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666843785?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:03","pubTimestamp":1788948238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，于2026年9月9日，该公司斥资262.98万港元回购15.25万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK1191","BK0196","BK1593","BK1515","600196","BK0096","BK0187","BK0028","BK0060","BK0183","BK0188","02196","BK0239","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666585821","title":"京東(09618.HK)發布新版京東App 推AI購物助手「東東」","url":"https://stock-news.laohu8.com/highlight/detail?id=2666585821","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666585821?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 16:09","pubTimestamp":1788941340,"startTime":"0","endTime":"0","summary":"京东全球科技探索者大会今日举行，京东发布新版京东App，增强现有购物模式，同时推出购物助手“东东”，融合AI对于用户需求的精准理解，从帮助用户找到一个商品，到理解用户现在需要解决什么问题，并调度海量商品和服务满足用户需求，让用户的购物决策更高效、让购物体验更省心。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20241101151338792_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20241101151338792_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543639/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543639/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0431992006.USD","LU0865486749.SGD","LU1794554557.SGD","LU0868486357.SGD","LU1808992512.USD","LU0211977185.USD","LU0327786744.USD","LU1044874839.SGD","IE00B3M56506.USD","LU1282649067.USD","LU0259732245.USD","LU0231483743.USD","BK1247","BK1589","BK1575","06618","SGXZ62798434.SGD","BK1571","LU0084288322.USD","LU0384037296.USD","LU0572944931.SGD","LU0228367735.SGD","LU0293314216.USD","BK1515","LU0588546209.SGD","LU1813983027.USD","BK1142","LU0228659784.USD","LU1251922891.USD","LU1366334578.USD","LU0345775950.USD","LU0348825331.USD","BK1583","LU0307460666.USD","LU1044876610.USD","LU0791590937.USD","LU0499858602.USD","86618","LU0456827905.SGD","LU0164880469.USD","LU0588545904.SGD","SGXZ86797644.SGD","LU0488056044.USD","LU1282651121.HKD","LU0359202008.SGD","LU0672654166.SGD","LU1023057109.AUD","SG9999001226.SGD","LU0594300419.USD","BK1610","BK1615","LU1770034418.SGD","LU0456846285.SGD","LU0320764599.SGD","LU1224444064.USD","SG9999002562.SGD","LU0469268626.HKD","LU0163747925.USD","LU0531971595.HKD","LU1719994722.HKD","LU0650527681.SGD","LU0149721374.USD","LU1481107354.HKD","LU2257852520.SGD","JD","LU0029875118.USD","LU0052750758.USD","LU1282649810.SGD","LU1770036033.HKD","LU0708995583.HKD","BK1619","IE00BGV7N243.SGD","LU0791591158.USD","LU2039709279.SGD","LU2242644610.SGD","LU0314109678.HKD","LU0456842615.SGD","SG9999002828.SGD","BK1502","LU0588545490.SGD","BK1249","09618","LU0417516902.SGD","LU0359201612.USD","LU0315179316.USD","LU0499858438.USD","LU0348805143.USD","IE00B29SXG58.USD","LU0140636845.USD","LU0164865239.USD","LU0543330483.HKD","LU0048580855.USD","LU0828237510.HKD","LU1282651048.USD","89618","LU0051755006.USD","LU0359201885.HKD","LU1044875133.USD","LU0417516738.SGD","LU0348735423.USD","LU0128522157.USD","LU1720050803.USD","LU0370786039.SGD","LU1366334651.USD","LU1303224171.USD","LU0871576103.HKD","LU0588545730.USD","LU1328277881.USD","LU0345776255.USD","IE0032431581.USD","BK1588","BK1591","LU0320764755.SGD","LU0315178854.USD","LU0039217434.USD","LU1642822792.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583145","title":"迪哲醫藥(688192.SH)：比瑞替尼治療瀰漫性大B細胞淋巴瘤研究成果獲《血液腫瘤期刊》發表","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583145","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666583145?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 15:56","pubTimestamp":1788940569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司自主研发的全球首创、可完全穿透血脑屏障的非共价LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤II期临床研究结果正式发表于国际权威血液学期刊《血液肿瘤期刊》。TAI-SHAN9研究入组患者既往接受过1至5线系统性治疗。研究结果显示，在50mg和75mg剂量下，比瑞替尼单药治疗在不同分子亚型中均展现出广谱的抗肿瘤活性，并呈现出可管理的安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK1515","BK1574","159938","BK1161","09939","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666304134","title":"《大行》里昂：中國創新藥板塊重返Alpha主導  宏觀波動或提供買入機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2666304134","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666304134?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 12:08","pubTimestamp":1788926880,"startTime":"0","endTime":"0","summary":"里昂发表报告指，中国创新药板块正重回以公司基本面与个股超额收益为主导的市场，公司特定基本面相对宏观因素的影响力回升。该行预期，随市场对创新药企临床及BD执行信心改善，基本面角色将愈趋重要；短期宏观波动或提供趁低买入、验证此观点的机会。该行认为，重大临床读出与BD活动加速，正面催化剂窗口正在打开。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543577/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1543577/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["IE00B031HY20.USD","LU0326950275.SGD","LU1820825898.SGD","LU1831875114.USD","BK1197","BK1521","LU0455707207.USD","BK1576","BK0209","SHTDY","LU1781817850.SGD","LU2097828474.EUR","01276","IE0008368742.USD","KURE","LU0072913022.USD","LU0540923850.HKD","LU1997245094.SGD","LU1951186391.HKD","LU2476274308.USD","LU1226287529.USD","LU1997245177.USD","LU2476274720.SGD","LU2328871848.SGD","600276","LU1997244956.HKD","BK0183","IE00BZ08YT58.USD","01801","603233","LU0880133367.SGD","IE00B543WZ88.USD","LU2097828714.EUR","BK1161","LU1226287792.SGD","LU0469268626.HKD","LU1807302812.USD","LU2097828631.EUR","LU0348767384.USD","LU2125910500.SGD","LU0348735423.USD","SG9999004311.SGD","603259","LU2097828805.USD","LU0405327148.USD","IE00BVYPNQ40.USD","LU0315179316.USD","IE00BGHQDM52.EUR","SG9999015945.SGD","BK0226","LU2045819591.USD","LU2488822045.USD","LU0634319403.HKD","SG9999015952.SGD","BK0028","LU2399975544.HKD","BK1191","IE00BVYPNP33.GBP","IE0008369823.USD","LU2242644610.SGD","LU0348827113.USD","LU1580142542.USD","LU0501845795.SGD","LU1046422090.SGD","02595","LU2039709279.SGD","LU0140636845.USD","BK1500","BK1589","BK0196","01177","BK1141","LU0244354667.USD","LU1226288170.HKD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU0640798160.USD","300765","LU1152091754.HKD","SG9999004220.SGD","BK1515","LU0348825331.USD","LU1064131003.USD","LU0561508036.HKD","BK1583","BK1593","LU1115378108.SGD","BK0239","LU0314109678.HKD","IE00BZ08YR35.GBP","LU2778985437.USD","LU1655091616.SGD","SG9999015978.USD","LU1328615791.USD","LU1008478684.HKD","BK0114","IE00BYV24P56.USD","LU1152091168.USD","LU1255011170.USD","LU0348784397.USD","LU2289578879.USD","09926","LU2148510915.USD","LU0463099449.HKD","LU1969619763.USD","03692","00867","LU1226287875.USD","IE00B5MMRT66.SGD","LU0320764599.SGD","LU0149534421.HKD","LU1813983027.USD","LU0348766576.USD","LU2580892789.USD","LU0607220059.USD","02162","LU1794554557.SGD","LU0417516902.SGD","LU1146622755.USD","LU1226288253.USD","LU1328277881.USD","LU0067412154.USD","IE00BMCWC346.EUR","LU0052750758.USD","SBHMY","LU1064130708.USD","LU0405327494.USD","IE00BPRC5H50.USD","LU0417516738.SGD","LU0417516571.SGD","LU0708995583.HKD","HK0000165453.HKD","LU0327786744.USD","LU1188198961.HKD","02359","BK1587","BK0060","LU1961090484.USD","BK0012","LU0572944931.SGD","BK1574","01093","BK0185","01099","LU2580892862.HKD","LU2097828557.USD","LU0502904849.HKD","LU1960683339.HKD","BK0188","LU0348783233.USD","SG9999015986.USD","LU2495084118.USD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666114301","title":"中銀國際：醫藥中報業績逐步修復 行業進入反轉周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2666114301","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666114301?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:54","pubTimestamp":1788922458,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中银国际发布研报称，医药板块上市公司26年中报已经披露完毕，整体看，医药行业整体增长韧性十足，结构性修复持续演绎。关注底部边际修复板块，如医疗器械、原料药以及药店等医疗器械细分板块来看，医疗设备呈弱复苏态势，高值耗材增长稳健，IVD板块触底回升，低值耗材板块盈利明显修复。IVD板块，低基数效应与海外业务持续放量驱动行业盈利显著修复。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159938","BK1515","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666304301","title":"阿里健康(00241)出現大手賣出110萬股，成交價$3.055，涉資336.05萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2666304301","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666304301?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 10:49","pubTimestamp":1788922140,"startTime":"0","endTime":"0","summary":"[大手成交]阿里健康(00241)在上午10:49出现大手卖出，成交量为110万，成交价为港币$3.055，涉资336.05万。至目前为止，股价跌2.707%，今日最高价为$3.14，而最低价为$3.055，总成交量为3.484千万股，总成交金额港币$1.07亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550868_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2609094711/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2609094711/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1501","00241","BK1189","BK1615","BK1617","BK1515","BK1247","BK1589","HK0000165453.HKD","BK1571","BK1610","BK1142","BK1584","BK1502","BK1591"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666308479","title":"我武生物董事長因個人原因辭職；諾華新藥III期臨床未達主要終點 | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666308479","media":"每日经济新闻","labels":["executive","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666308479?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 07:01","pubTimestamp":1788908468,"startTime":"0","endTime":"0","summary":"丨2026年9月9日星期三丨NO.1诺华制药DM1药物III期临床未达主要终点9月8日，诺华制药宣布，其评估del-desiran治疗1型强直性肌营养不良（DM1）的III期HARBOR研究未达到主要终点。公司表示，将进一步分析完整数据，并与监管机构沟通后确定后续开发路径。点评：消息放出后，诺华股价明显受挫，反映资本市场对该管线预期大幅下调。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093868484469.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093868484469.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","159938","IE0009355771.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","BK4007","MEDX","LU0070302665.USD","IE00BJJMRZ35.SGD","LU0208291251.USD","LU0211331839.USD","BK4532","BK4585","LU0320765489.SGD","IE00B2B36J28.USD","BK0028","BK1161","IE00B4R5TH58.HKD","300357","BK1515","BK4588","BK0239","NVS","PPH","09939","BK4578","IE0002141913.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665620376","title":"港股震盪走弱：資源醫藥「扛大旗」，科技股「摔跟頭」","url":"https://stock-news.laohu8.com/highlight/detail?id=2665620376","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665620376?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 22:13","pubTimestamp":1788876780,"startTime":"0","endTime":"0","summary":"今日(9月8日)，港股市场整体震荡走弱，各大核心指数涨跌分化明显。截至收盘，恒生指数微跌0.38%，报25317.18点，单日下跌95.94点；国企指数同步小幅下行，跌幅0.38%，收报8397.32点；恒生科 ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20260908/c679714830.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["XLK","02834","09834","BK1147","09939","TTTN","03086","BK4585","BK1574","07522","09086","07266","KCAI","VXUS","159938","BK1515","07261","BK4588","BK1161","03455","03034","07568","VGT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665758793","title":"同源康醫藥-B(02410)董事長、執行董事兼總裁吳豫生擬增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2665758793","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665758793?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:23","pubTimestamp":1788873797,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司董事长、执行董事兼总裁吴豫生博士(吴博士)已告知本公司，吴博士近日于公开市场购买本公司股份，未来可能继续根据市场情况购买本公司股份，目前预计增持总金额不超过200万港元。吴博士已向本公司承诺，他在未来一个月内通过增持获得的本公司股份将分别自购入日起自愿锁定六个月，并在锁定期内不会出售或通过其他方式转让有关股份。吴博士表示，本次股份增持的资金来自其自有资金。此次增持股份彰显其对本集团未来发展前景的坚定信念及充分信心。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1515","BK1161","02410","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665537323","title":"四川甘孜：農機助力川西高原秋收","url":"https://stock-news.laohu8.com/highlight/detail?id=2665537323","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665537323?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 21:02","pubTimestamp":1788872520,"startTime":"0","endTime":"0","summary":"9月8日，收割机助力甘孜县昔色乡格虾村收割青稞。中新社记者 王磊 摄9月8日，甘孜县昔色乡格虾村村民把青稞粒从收割机上转运到拖拉机。9月，四川省甘孜藏族自治州各地进入秋收的繁忙季节，田间地头一片忙碌的景象。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-09-08/doc-inircrns4449085.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-09-08/doc-inircrns4449085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["00241","BK1584","BK1615","BK1589","BK1501","BK1571","BK1502","BK1617","BK1610","HK0000165453.HKD","BK1515","BK1591","BK1247","BK1189","BK1142"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665135320","title":"勁方醫藥-B(02595)9月8日斥資154.18萬港元回購5.7萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2665135320","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665135320?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:09","pubTimestamp":1788869377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，劲方医药-B(02595)发布公告，于2026年9月8日，该公司斥资154.18万港元回购5.7万股。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493534.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02595","159938","BK1515","BK1574","09939","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665320617","title":"禮邦醫藥-B(09637)：AP308治療IgA腎病的新藥臨床試驗申請獲美國食品藥品監督管理局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2665320617","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665320617?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:03","pubTimestamp":1788869000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，礼邦医药-B 发布公告，公司近日就AP308的新药临床试验申请获美国食品药品监督管理局批准，将启动一项AP308用于治疗IgA肾病的首次人体临床试验。就公司所知，AP308为首个获准开展临床试验的IgA蛋白酶类IgAN候选药物。该平台具有优异的稳定性及成药性，并可在保留蛋白酶对IgA1高效切割活性的同时，显著延长药物体内半衰期、降低肾脏清除并减弱免疫原性，为长效、低频次给药奠定基础。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493525.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BMED","BK1574","MDTX","09939","IBBJ","159151","IBBQ","159938","PSYK","BK1515","BK1161","09637"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":4,"totalSize":209,"code":"91000000","status":"200"}]}}